Reuters -- A U.S. drug regulatory advisory panel said on Tuesday current labeling for pediatric uses of Bristol-Myers Squibb Co's (BMY.N) antipsychotic drug, Abilify, does not adequately warn of the risk of excessive weight gain.
Reuters -- A U.S. drug regulatory advisory panel said on Tuesday current labeling for pediatric uses of Bristol-Myers Squibb Co's (BMY.N) antipsychotic drug, Abilify, does not adequately warn of the risk of excessive weight gain.
